Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data

被引：0
|
作者：
Holland C Detke
Fangyi Zhao
Michael M Witte
机构：
[1] Eli Lilly and Company,
[2] Lilly USA,undefined
[3] LLC,undefined
来源：
BMC Psychiatry | / 12卷
关键词：
Olanzapine; Long-acting injection; Pamoate; Haloperidol; Effect size; Onset; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Comparison of hospitalization risk before and after changing from risperidone long-acting injection to another long-acting injection or oral antipsychotic in patients with schizophrenia: Mirror-image study
    Suzuki, Hidenobu
    Hibino, Hiroyuki
    Inoue, Yuichi
    Takaya, Atsuhiko
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2016, 70 (08) : 365 - 366
  • [22] Olanzapine long-acting injection vs oral olanzapine in schizophrenia outpatients: a 2-year, randomized, open-label study
    Detke, H.
    Weiden, P. J.
    Lambert, T.
    Llorca, P. M.
    Choukour, M.
    Watson, S. B.
    Brunner, E.
    Ascher-Svanum, H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S464 - S464
  • [23] Cost effectiveness analysis of long-acting risperidone injection compared with olanzapine and fluphenazine decanoate in patients with schizophrenia
    Baca, E
    Bobes, J
    Cañas, F
    Leal, C
    Salvador, L
    Rubio, M
    Magaz, S
    Badía, X
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S238 - S238
  • [24] A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
    Atkins, Susan
    Detke, Holland C.
    McDonnell, David P.
    Case, Michael G.
    Wang, Shufang
    BMC PSYCHIATRY, 2014, 14
  • [25] A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
    Susan Atkins
    Holland C Detke
    David P McDonnell
    Michael G Case
    Shufang Wang
    BMC Psychiatry, 14
  • [26] An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
    Lauriello, John
    Lambert, Tim
    Andersen, Scott
    Lin, Daniel
    Taylor, Cindy C.
    McDonnell, David
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (05) : 790 - 799
  • [27] Postinjection delirium/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study
    Meyers, Kristin J.
    Upadhyaya, Himanshu P.
    Landry, John L.
    Chhabra-Khanna, Rashna
    Falk, Deborah M.
    Rao, Balasubramanya Seetharama
    Jones, Meghan E.
    BJPSYCH OPEN, 2017, 3 (04): : 186 - 192
  • [28] Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable
    Rosa, Fernanda
    Schreiner, Andreas
    Thomas, Pierre
    Sherif, Tarek
    CLINICAL DRUG INVESTIGATION, 2012, 32 (04) : 267 - 279
  • [29] Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable
    Fernanda Rosa
    Andreas Schreiner
    Pierre Thomas
    Tarek Sherif
    Clinical Drug Investigation, 2012, 32 : 267 - 279
  • [30] Olanzapine long-acting injection: An 8-week double-blind, randomized, placebo-controlled study in acutely-ill patients with schizophrenia
    Detke, H. C.
    McDonnell, D. P.
    Lauriello, J.
    Lambert, T.
    Andersen, S. W.
    Lin, D.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 152 - 152
12345